Published in Nat Med on September 16, 2002
Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 3.69
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation (2010) 2.85
Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A (2004) 2.79
Pathology of pulmonary hypertension. Clin Chest Med (2007) 2.34
Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol (2007) 1.85
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol (2004) 1.51
Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. Am J Respir Crit Care Med (2011) 1.41
Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling. Am J Pathol (2010) 1.33
Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol (2011) 1.30
miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol (2012) 1.29
Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol (2007) 1.23
Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway. Proc Natl Acad Sci U S A (2003) 1.17
Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1. Am J Respir Cell Mol Biol (2005) 1.17
The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol (2008) 1.11
Pulmonary hypertension: therapeutic targets within the serotonin system. Br J Pharmacol (2008) 1.11
Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J (2007) 1.06
Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction. Exp Clin Psychopharmacol (2008) 1.06
Molecular mechanisms of pulmonary arterial remodeling. Mol Med (2014) 1.05
(1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity. Eur J Pharmacol (2009) 1.05
Upregulation of osmo-mechanosensitive TRPV4 channel facilitates chronic hypoxia-induced myogenic tone and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2011) 1.01
S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology (Berl) (2008) 1.00
Recent advances in clinical practice challenges and opportunities in the management of obesity. Gut (2014) 0.98
Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice. Pharmacol Biochem Behav (2008) 0.98
Potential drug targets for calcific aortic valve disease. Nat Rev Cardiol (2014) 0.98
Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab (2010) 0.98
TRPV4 channel contributes to serotonin-induced pulmonary vasoconstriction and the enhanced vascular reactivity in chronic hypoxic pulmonary hypertension. Am J Physiol Cell Physiol (2013) 0.97
Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf (2009) 0.96
Signal transduction in the development of pulmonary arterial hypertension. Pulm Circ (2013) 0.95
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest (2013) 0.93
Safety of antiobesity drugs. Ther Adv Drug Saf (2013) 0.93
Smoking related diseases: the central role of monoamine oxidase. Int J Environ Res Public Health (2011) 0.93
Mechanosensitive ion channel Piezo2 is important for enterochromaffin cell response to mechanical forces. J Physiol (2016) 0.92
Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension. Cardiovasc Res (2013) 0.90
Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm Circ (2013) 0.90
N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: a Novel Class of Selective, Nonbasic, Nitrogen-Containing κ-Opioid Receptor Ligands. ACS Med Chem Lett (2010) 0.88
Arterial expression of 5-HT2B and 5-HT1B receptors during development of DOCA-salt hypertension. BMC Pharmacol (2003) 0.87
Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus. Am J Physiol Lung Cell Mol Physiol (2011) 0.87
Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation. Eur J Pharmacol (2011) 0.87
Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med (2008) 0.87
Molecular Determinants for Ligand Binding at Serotonin 5-HT2A and 5-HT2C GPCRs: Experimental Affinity Results Analyzed by Molecular Modeling and Ligand Docking Studies. Int J Quantum Chem (2012) 0.84
Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction. J Pharmacol Toxicol Methods (2011) 0.83
Deconstructing antiobesity compound action: requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects. Neuropsychopharmacology (2010) 0.83
Transglutaminase 2-mediated serotonylation in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2013) 0.82
Altered gene expression in pulmonary tissue of tryptophan hydroxylase-1 knockout mice: implications for pulmonary arterial hypertension. PLoS One (2011) 0.82
The use of serotonergic drugs to treat obesity--is there any hope? Drug Des Devel Ther (2011) 0.82
Serotonin decreases alveolar epithelial fluid transport via a direct inhibition of the epithelial sodium channel. Am J Respir Cell Mol Biol (2009) 0.82
Serotonin contributes to high pulmonary vascular tone in a sheep model of persistent pulmonary hypertension of the newborn. Am J Physiol Lung Cell Mol Physiol (2013) 0.80
5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure. Biomed Res Int (2015) 0.80
Serotonin paracrine signaling in tissue fibrosis. Biochim Biophys Acta (2012) 0.79
New insights on receptor-dependent and monoamine oxidase-dependent effects of serotonin in the heart. J Neural Transm (Vienna) (2007) 0.79
Microvessel mechanobiology in pulmonary arterial hypertension: cause and effect. Hypertension (2014) 0.78
Platelet TLR4: a critical link in pulmonary arterial hypertension. Circ Res (2014) 0.78
New concepts in the invasive and non invasive evaluation of remodelling of the right ventricle and pulmonary vasculature in pulmonary arterial hypertension. Open Respir Med J (2009) 0.78
Pulmonary hypertension in obstructive sleep apnea: is it clinically significant? A critical analysis of the association and pathophysiology. Pulm Circ (2015) 0.78
Thrombosis, platelets, microparticles and PAH: more than a clot. Drug Discov Today (2014) 0.78
Bone marrow-derived vascular modulatory cells in pulmonary arterial hypertension. Pulm Circ (2013) 0.77
The 5-HT2C receptor agonist, lorcaserin, and the 5-HT6 receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour. Psychopharmacology (Berl) (2015) 0.76
Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats. J Anesth (2015) 0.76
Genomics of pulmonary arterial hypertension: implications for therapy. Heart Fail Clin (2010) 0.76
Hypothesis: neuroendocrine mechanisms (hypothalamus-growth hormone-STAT5 axis) contribute to sex bias in pulmonary hypertension. Mol Med (2015) 0.76
Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension. PLoS One (2016) 0.76
Non-conventional features of peripheral serotonin signalling - the gut and beyond. Nat Rev Gastroenterol Hepatol (2017) 0.75
Vesicle miR-195 derived from Endothelial Cells Inhibits Expression of Serotonin Transporter in Vessel Smooth Muscle Cells. Sci Rep (2017) 0.75
Hypoxia facilitates neurogenic dural plasma protein extravasation in mice: a novel animal model for migraine pathophysiology. Sci Rep (2015) 0.75
Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther (2016) 0.75
STAT5a/b contribute to sex bias in vascular disease: A neuroendocrine perspective. JAKSTAT (2015) 0.75
Pulmonary vascular disease related to hemodynamic stress in the pulmonary circulation. Compr Physiol (2011) 0.75
Serotonin 2B receptor (5-HT2B R) signals through prostacyclin and PPAR-ß/δ in osteoblasts. PLoS One (2013) 0.75
Drug-induced pulmonary arterial hypertension: a review. Heart Fail Rev (2017) 0.75
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med (1996) 11.76
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med (1998) 7.08
Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med (1995) 6.97
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J (2009) 6.64
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet (2008) 5.01
Organization and sequence studies of the 17-piece chicken conalbumin gene. Nature (1979) 4.36
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med (2001) 3.29
Inflammation in pulmonary arterial hypertension. Eur Respir J (2003) 3.18
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J (2010) 2.90
Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J (2005) 2.83
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet (2000) 2.82
Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med (1995) 2.76
Dinoflagellate 17S rRNA sequence inferred from the gene sequence: Evolutionary implications. Proc Natl Acad Sci U S A (1986) 2.74
Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest (2001) 2.59
BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet (2000) 2.51
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J (2009) 2.41
Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J (2004) 2.40
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J (2006) 2.39
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO J (1983) 2.28
Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med (2000) 2.25
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J (1998) 2.14
Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax (2005) 2.03
Primary pulmonary hypertension and fenfluramine use. Br Heart J (1993) 2.02
Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J (2005) 1.98
Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med (2007) 1.86
Increased plasma serotonin in primary pulmonary hypertension. Am J Med (1995) 1.86
Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J (2009) 1.85
Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J (2006) 1.78
Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci U S A (2000) 1.75
[Guidelines for the diagnosis and treatment of pulmonary hypertension]. Rev Mal Respir (2010) 1.74
Chronic thromboembolic pulmonary hypertension. Eur Respir J (2004) 1.74
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J (2004) 1.73
Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood (2001) 1.71
Stromal cells from human long-term marrow cultures are mesenchymal cells that differentiate following a vascular smooth muscle differentiation pathway. Blood (1993) 1.71
High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest (1999) 1.70
Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. J Am Coll Cardiol (2001) 1.65
Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy (2004) 1.61
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem (2002) 1.61
The use of combination therapy in pulmonary arterial hypertension: new developments. Eur Respir Rev (2009) 1.60
Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol (1997) 1.59
Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events. Arthritis Rheum (2002) 1.54
Thrombotic risk factors in pulmonary hypertension. Eur Respir J (2000) 1.54
Double lung transplantation in situs inversus with Kartagener's syndrome. Paris-Sud University Lung Transplant Group. J Thorac Cardiovasc Surg (1994) 1.53
Haemodynamic evaluation of pulmonary hypertension. Eur Respir J (2002) 1.53
Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol (1990) 1.53
Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res (1991) 1.51
Association of pulmonary aspergilloma and allergic bronchopulmonary aspergillosis. Eur Respir Rev (2010) 1.51
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J (2007) 1.51
Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J (1998) 1.51
Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med (2000) 1.51
Embolic and bleeding events after modified Bentall procedure in selected patients. Heart (2006) 1.47
Prominent psychiatric features and early onset in an inherited prion disease with a new insertional mutation in the prion protein gene. Brain (1999) 1.46
Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med (1995) 1.46
Validation of a live animal model for training in endoscopic hemostasis of upper gastrointestinal bleeding ulcers. Endoscopy (2013) 1.46
Pulmonary vascular disorders in portal hypertension. Eur Respir J (1998) 1.44
The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J (2007) 1.43
Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr (1997) 1.42
Prioritised research agenda for prevention and control of chronic respiratory diseases. Eur Respir J (2010) 1.41
[Adult asthma exacerbations in questions]. Rev Mal Respir (2010) 1.40
Olfactory identification deficits in HIV infection. Am J Psychiatry (1991) 1.40
Evidence of endogenous volatile organic compounds as biomarkers of diseases in alveolar breath. Ann Pharm Fr (2013) 1.40
Amelioration of reperfusion injury by pentoxifylline after lung transplantation. The Université Paris-Sud Lung Transplant Group. J Heart Lung Transplant (1995) 1.40
Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax (2004) 1.40
[Lung transplantation]. Presse Med (1989) 1.39
Fatal rupture of pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasis and severe PAH. Eur Respir Rev (2009) 1.39
Management of severe pulmonary arterial hypertension. Eur Respir Rev (2010) 1.38
Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest (1994) 1.38
Pulmonary veno-occlusive disease. Eur Respir J (2009) 1.37
Pentamidine and pancreatitis. Ann Intern Med (1986) 1.34
Serotonin synchronises convergent extension of ectoderm with morphogenetic gastrulation movements in Drosophila. Mech Dev (1999) 1.33